1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. ABBOTT INDIA LTD.
Abbott India Ltd.
NSE: ABBOTINDIA | BSE: 500488

Abbott Live Share Price Today, Share Analysis and Chart

Expensive Performer
BasketIn 1 Starfolio Basket
aboutAbbott India Limited is a significant player in the Indian pharmaceutical industry, functioning as a subsidiary of the global healthcare leader Abbott Laboratories. The company focuses on providing a diverse range of science-based healthcare products... Read More
Ask AI about Abbott
25635.00-510.00(-1.95%)

Near 52W Low of ₹24650.00

8,991
NSE+BSE Volume

NSE 30 Oct, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Board Meeting
The next board meeting for Abbott is on 05 Nov 2026 for the purpose of Quarterly Results See details
Loading...
- / 100
- / 100
42.7 / 100
Expensive PerformerThese stocks are strong in quality but with mid-range technicals. Their valuations are expensiveView SimilarEmbed DVM
Analyst Price Target
-

14

S

9

W

7

O

1

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

13Positive9Negative

Pass in checklist59.1%

045
55
100

PE Valuation Check

Right Now
Undervalued
43.1%
1 Year Forward
Undervalued
53%
INSIGHTAbbott is undervalued at both current PE and future earnings estimates.

Abbott Stock Price Analysis

Day Price Range

-2.0% 1 Day return
25635 (LTP)
25,55526,455
LowHigh

Week Price Range

2.4% 1 Week return
25635 (LTP)
24,80526,495
LowHigh

Month Price Range

-6.0% 1 Month return
25635 (LTP)
24,65027,495
LowHigh

52 Week Price Range

-13.4% 1 Year return
25635 (LTP)
24,65030,655
LowHigh
View full Price History/Seasonality

Abbott Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Miss

Abbott's Revenue was lower than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
730.4
AVG. ESTIMATE
811.8
LOW ESTIMATE
767.6
HIGH ESTIMATE
866.8
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 11.1% in FY27

Consensus Recommendation

8 ANALYST Recommendations
BUY

The consensus recommendation from 8 analysts for Abbott is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Abbott Technical Analysis

Abbott EMA & SMA

Bearish-8
0 bullish, 8 bearish
Bullish0
Bearish8
5 Day25785.7
10 Day25782.3
12 Day25803.6
20 Day25910.1
26 Day25985.9
50 Day26217.3
100 Day26487.8
200 Day27014.3

Abbott Delivery And Volume

Daily Avg. Delivery Volume %
30 Oct, 202643.6%
Week59.7%
Month61.7%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Abbott Resistance and Support

25881.67
Pivot
First Resistance26208.3
Second Resistance26781.7
Third Resistance27108.3
First Support25308.3
Second Support24981.7
Third Support24408.3
Day RSI45.5
Day MACD-182.4
Day MFI42.5
Day MACD Signal Line-204.8

Abbott Beta

1 Month0.2
1 Year0.3
3 Month0.2
3 Year0.4

Abbott Price Change Analysis

↓-6%
Over 1 Month
LowHigh
2465027495
↓-7.0%
Over 3 Months
LowHigh
2465028635
↑0.6%
Over 6 Months
LowHigh
2465028940
↓-13.4%
Over 1 Year
LowHigh
2465030655
All Technicals →

Abbott Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Abbott Capital India LimitedPromoter10,719,09750.4 %
Sbi Nifty Midcap 150 Index FundDii319,7841.5 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Abbott Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
RELIANCE MUTUAL FUND (SCHEME RELIANCE CAPITAL TRUSTEE CO.BulkPurchase17 May 20111437199,441NSE
ABBOTT CAPITAL INDIA LIMITEDBulkSell17 May 20111437.93224,000NSE
All deals
All insider trades

Abbott Corporate Actions

Abbott Dividend history and yield

Abbott dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Abbott dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
124 Jul 2026
131SPECIAL24 Jul 2026Equity Share
224 Jul 2026
525FINAL24 Jul 2026Equity Share
325 Jul 2025
475FINAL25 Jul 2025Equity Share
419 Jul 2024
410FINAL19 Jul 2024Equity Share
521 Jul 2023
145SPECIAL21 Jul 2023Equity Share

Abbott Board Meetings

Abbott past and upcoming board meetings.

#Ex-Date
PurposeNotes
105 Nov 2026
Quarterly Results-
212 Aug 2026
Quarterly Results-
311 May 2026
Audited Results & Final Dividend-
412 Feb 2026
Quarterly Results-
506 Nov 2025
Quarterly Results-
All Corporate Actions

Abbott Research Reports

Abbott research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
102 Sep 2026BOB Capital Markets Ltd.3083925945Buy18.86%-1.19%pdf
212 May 2026BOB Capital Markets Ltd.3645727280Buy33.64%-6.03%pdf
311 May 2026ICICI Direct
Target
3240026900Buy20.45%-4.7%pdf
412 Feb 2026ICICI Direct3215026460Buy21.5%-3.12%pdf
526 Nov 2025BOB Capital Markets Ltd.4000029440Buy35.87%-12.92%pdf
All Reports of Abbott

Abbott Corporate Filings

Abbott BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
26 Oct 2026
Abbott India Ltd - 500488 - Board Meeting Intimation for Considering And Approving The Unaudited Financial Results Of The Company For The Second Quarter And Half Year Ended September 30, 2026
Abbott India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2026.
PDF
06 Oct 2026
Abbott India Ltd - 500488 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.
PDF
02 Oct 2026
Abbott India Ltd - 500488 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisement - Special Window for Transfer and Dematerialization of Physical Securities.
PDF
28 Sep 2026
Abbott India Ltd - 500488 - Closure of Trading Window
Closure of Trading Window for declaration of Unaudited Financial Results of the Company for the quarter ending September 30, 2026.
PDF
07 Sep 2026
Abbott India Ltd - 500488 - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
Resignation of Company Secretary and Compliance Officer of the Company.
PDF
VIEW ALL

Abbott DocumentsAsk MarketMind AI

Abbott Earnings Call

Abbott earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
03 Oct 2022ABBOTT INDIA LTD. - 500488 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
29 Sep 2022Investor Day: Abbott IndiaAudioVideo
28 Sep 2022ABBOTT INDIA LTD. - 500488 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
28 Jun 2021Abbott India Ltd - 500488 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
view all

Abbott Annual Reports

Abbott financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link
2022Annual Report Mar-2022Link

Abbott - Company Profile

Abbott Management Structure

Abbott management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Sangeeta ShettyCompany Secretary,Compliance Officer-Mar 26
Ms. Maithilee MistryChief Financial Officer-Mar 26
Mr. Prithwish BanerjiCommercial Director(Womens Health Vaccines,International Business)-Mar 26
Mr. Harshraj MadanDirector(Commercial,Business.)-Mar 26
Mr. Anuj MehraCommercial Director(Neurolife,GenNext,Vaccines)-Mar 26
Mr. Jejoe KarankumarDirector(Medical Affairs)-Mar 26
Mr. Devesh ChoudhariDirector(Finance)-Mar 26
Ms. Vinutha MuftiDirector(Human Resources Services)-Mar 26
Ms. Richa TripathiAssociate Director(Sales Force Effectiveness,Project Management Office)-Mar 26
Ms. Anushree KunhambuAssociate Director(New Product Introduction,Therapy Area Strategy)-Mar 26
Tushar SinghPlant Director(Goa.)-Mar 26
Pradnya DeshpandeAssociate Director(Site Quality)-Mar 26
Mr. Naresh TondareAssociate Director(Regulatory Affairs)-Mar 26

Abbott Board of Directors

Abbott Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
Kartik RajendranExecutive Director & MD644Mar 26
Munir ShaikhChairman(Non Exe)&Dir(Non-Ind)34Mar 26
Sudarshan JainIndependent Non Exe. Director32Mar 26
Shalini KamathIndependent Non Exe. Director32Mar 26
Kaiyomarz MarfatiaNon-Exec & Non-Independent Dir24Mar 26
Vivek MohanNon-Exec & Non-Independent Dir-Mar 26
Darshan GadaNon-Exec & Non-Independent Dir-Mar 26
James WennerNon Executive Director-Mar 26
Neeraj JainIndependent Non Exe. Director-Mar 26
Sangeeta ShettyCompany Sec. & Compli. Officer-Mar 26

Abbott Brands

Brands owned by Abbott

LOGOBRAND NAME
Acitrom
Bactrim
Cleanance gel
D3 Shot Sachets
LOGOBRAND NAME
Etody
Fabolite
Famtac
Febustat
LOGOBRAND NAME
Paraxin
Pathvysion
Pedialyte
Pediasure
LOGOBRAND NAME
TwoCal HN
Udiliv
Ultrazyme
Uvox
Website: www.abbott.co.in

About the company - Business Profile

Abbott India Limited is a significant player in the Indian pharmaceutical industry, functioning as a subsidiary of the global healthcare leader Abbott Laboratories. The company focuses on providing a diverse range of science-based healthcare products across multiple therapeutic areas, including gastroenterology, women's health, metabolics, central nervous system, and vaccines. With a legacy spanning over eight decades in India, the company maintains a strong market presence through trusted brands and an extensive distribution network that engages with healthcare professionals nationwide.

Key Points

  • Key Facts: Founded in 1944, Abbott India Limited is headquartered in Mumbai, Maharashtra. It is a subsidiary of Abbott Capital India Limited, which holds a majority stake of 74.99%. The company is listed on both the BSE Limited and the National Stock Exchange of India Limited.
  • Operations and Resources: The company operates a formulation plant in Goa and utilizes a network of independent contract manufacturers to support its production requirements. It employs a digitally empowered sales force to ensure broad reach across the Indian market.
  • Market and Significance: Abbott India holds leading positions in several therapeutic categories. Its brands, such as Digene, Cremaffin, Duphalac, Thyronorm, and Vertin, are highly recognized in the Indian healthcare ecosystem. The company focuses exclusively on the Pharmaceuticals segment within the Indian domestic market.
  • Business Model: The company’s business model centers on the development, manufacturing, and marketing of pharmaceutical products. It excels in lifecycle management of its legacy brands and successfully introduces new, differentiated therapies and preventive care offerings.
  • Revenue Breakdown (FY 2024-25):
    • Total Revenue from Operations: ₹6,409.15 Crores (Growth of 9.6% over FY 2023-24).
    • Geographical Region: The company primarily serves the Indian domestic market.
    • Segment: 100% of revenue is derived from the Pharmaceuticals segment.
  • Key Products and Performance:
    • Gastroenterology: Includes brands like Udiliv, Duphalac, and Cremaffin.
    • Metabolics: Significant presence with Thyronorm for thyroid management.
    • Central Nervous System: Key brand Vertin for vertigo treatment.
    • Women's Health: Offers therapies such as Duphaston.
    • Vaccines: Provides a range of pediatric and adult vaccines, including Influvac.
  • Financial Highlights (FY 2024-25):
    • EBITDA: ₹1,970 Crores (Margin: 30.7%).
    • Profit After Tax (PAT): ₹1,414.44 Crores (Growth: 17.8%).
    • Earnings Per Share (EPS): ₹665.62.
    • Return on Average Capital Employed (ROCE): 35.7%.
  • Employee Trends: As of March 31, 2024, the company had 3,814 permanent employees. The company recently recognized an incremental cost of ₹35.10 Crores in Q3 FY 2025 related to the implementation of New Labour Codes.
  • Strategic Initiatives: Current strategies focus on digital transformation of field force operations, expanding the portfolio into high-growth therapeutic areas, and enhancing patient engagement through health awareness programs and diagnostic support.

References

  1. Annual Report Mar 2025
  2. Annual Report Mar 2024
  3. Quarterly Results Dec 2025
  4. Quarterly Results Sep 2025

Abbott FAQ

Abbott today is trading in the red, down by 1.95% at ₹25,635.
Abbott is currently trading down 1.95% on an intraday basis. In the past week the stock rose 2.42%. Stock has been down 6.97% in the past quarter and fell 13.4% in the past year. You can view this in the share price history/seasonality section.
Abbott is listed on NSE with the ticker ABBOTINDIA and on BSE as 500488. It's currently trading on NSE at a share price of ₹25,635 and on BSE with a share price of ₹25,570.2.
The market cap of Abbott is ₹54,472.58 Cr. as of Oct 30, 2026.
Abbott announced a SPECIAL dividend of 1310% which equals ₹131 in Jul 24, 2026.The last three ex-dates for Abbott were Jul 24, 2026, Jul 25, 2025 and Jul 19, 2024. To view the full dividend history of Abbott click here.
Abbott has never issued stock splits or bonus shares since the time of its listing on the BSE/NSE exchanges.
Abbott reported ₹1,889.05 Cr. in revenue, ₹428.52 Cr. in net profit, and ₹597.87 Cr. in EBITD as of Aug 12, 2026 for Q1 FY26-27.
According to the predictions of 8 analysts, the share price prediction for Abbott is ₹32,467.38 with an upside of 27%.
The PE ratio of Abbott is 33.74 as of Oct 30, 2026.
The PB ratio of Abbott is 10.47 as of Oct 30, 2026.
You can view the latest analyst reports on the Abbott reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×